1.71
-0.12(-6.56%)
Currency In USD
| Previous Close | 1.83 |
| Open | 1.8 |
| Day High | 1.82 |
| Day Low | 1.69 |
| 52-Week High | 4.07 |
| 52-Week Low | 0.81 |
| Volume | 506,371 |
| Average Volume | 312,567 |
| Market Cap | 18.46M |
| PE | -1.46 |
| EPS | -1.17 |
| Moving Average 50 Days | 1.29 |
| Moving Average 200 Days | 1.24 |
| Change | -0.12 |
If you invested $1000 in Marker Therapeutics, Inc. (MRKR) 10 years ago, it would be worth $26.89 as of January 14, 2026 at a share price of $1.71. Whereas If you bought $1000 worth of Marker Therapeutics, Inc. (MRKR) shares 5 years ago, it would be worth $80.28 as of January 14, 2026 at a share price of $1.71.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer
GlobeNewswire Inc.
Jan 05, 2026 12:00 PM GMT
Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with pancreatic cancer in Arm A of the clinical study Study highlights correlation between the clinical benefit an
Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
GlobeNewswire Inc.
Nov 05, 2025 12:30 PM GMT
HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and so
Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting
GlobeNewswire Inc.
Nov 03, 2025 2:15 PM GMT
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data MT-601 demonstrated robust safety profile with no dose limiting toxicities (DLTs) or immune-effector cell associ